219 related articles for article (PubMed ID: 35875815)
1. Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study.
Bahmer T; Borzikowsky C; Lieb W; Horn A; Krist L; Fricke J; Scheibenbogen C; Rabe KF; Maetzler W; Maetzler C; Laudien M; Frank D; Ballhausen S; Hermes A; Miljukov O; Haeusler KG; Mokhtari NEE; Witzenrath M; Vehreschild JJ; Krefting D; Pape D; Montellano FA; Kohls M; Morbach C; Störk S; Reese JP; Keil T; Heuschmann P; Krawczak M; Schreiber S;
EClinicalMedicine; 2022 Sep; 51():101549. PubMed ID: 35875815
[TBL] [Abstract][Full Text] [Related]
2. Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP).
Horn A; Krist L; Lieb W; Montellano FA; Kohls M; Haas K; Gelbrich G; Bolay-Gehrig SJ; Morbach C; Reese JP; Störk S; Fricke J; Zoller T; Schmidt S; Triller P; Kretzler L; Rönnefarth M; Von Kalle C; Willich SN; Kurth F; Steinbeis F; Witzenrath M; Bahmer T; Hermes A; Krawczak M; Reinke L; Maetzler C; Franzenburg J; Enderle J; Flinspach A; Vehreschild J; Schons M; Illig T; Anton G; Ungethüm K; Finkenberg BC; Gehrig MT; Savaskan N; Heuschmann PU; Keil T; Schreiber S
Infection; 2021 Dec; 49(6):1277-1287. PubMed ID: 34642875
[TBL] [Abstract][Full Text] [Related]
3. Predictors of non-recovery from fatigue and cognitive deficits after COVID-19: a prospective, longitudinal, population-based study.
Hartung TJ; Bahmer T; Chaplinskaya-Sobol I; Deckert J; Endres M; Franzpötter K; Geritz J; Haeusler KG; Hein G; Heuschmann PU; Hopff SM; Horn A; Keil T; Krawczak M; Krist L; Lieb W; Maetzler C; Montellano FA; Morbach C; Neumann C; Nürnberger C; Russ AK; Schmidbauer L; Schmidt S; Schreiber S; Steigerwald F; Störk S; Zoller T; Maetzler W; Finke C;
EClinicalMedicine; 2024 Mar; 69():102456. PubMed ID: 38333368
[TBL] [Abstract][Full Text] [Related]
4. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study.
Hartung TJ; Neumann C; Bahmer T; Chaplinskaya-Sobol I; Endres M; Geritz J; Haeusler KG; Heuschmann PU; Hildesheim H; Hinz A; Hopff S; Horn A; Krawczak M; Krist L; Kudelka J; Lieb W; Maetzler C; Mehnert-Theuerkauf A; Montellano FA; Morbach C; Schmidt S; Schreiber S; Steigerwald F; Störk S; Maetzler W; Finke C
EClinicalMedicine; 2022 Nov; 53():101651. PubMed ID: 36133318
[TBL] [Abstract][Full Text] [Related]
5. Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort.
Gentilotti E; Górska A; Tami A; Gusinow R; Mirandola M; Rodríguez Baño J; Palacios Baena ZR; Rossi E; Hasenauer J; Lopes-Rafegas I; Righi E; Caroccia N; Cataudella S; Pasquini Z; Osmo T; Del Piccolo L; Savoldi A; Kumar-Singh S; Mazzaferri F; Caponcello MG; de Boer G; Hara GL; ; De Nardo P; Malhotra S; Canziani LM; Ghosn J; Florence AM; Lafhej N; van der Gun BTF; Giannella M; Laouénan C; Tacconelli E
EClinicalMedicine; 2023 Aug; 62():102107. PubMed ID: 37654668
[TBL] [Abstract][Full Text] [Related]
6. Long-term symptom severity and clinical biomarkers in post-COVID-19/chronic fatigue syndrome: results from a prospective observational cohort.
Legler F; Meyer-Arndt L; Mödl L; Kedor C; Freitag H; Stein E; Hoppmann U; Rust R; Wittke K; Siebert N; Behrens J; Thiel A; Konietschke F; Paul F; Scheibenbogen C; Bellmann-Strobl J
EClinicalMedicine; 2023 Sep; 63():102146. PubMed ID: 37662515
[TBL] [Abstract][Full Text] [Related]
7. Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort.
Shi Y; Strobl R; Apfelbacher C; Bahmer T; Geisler R; Heuschmann P; Horn A; Hoven H; Keil T; Krawczak M; Krist L; Lemhöfer C; Lieb W; Lorenz-Depiereux B; Mikolajczyk R; Montellano FA; Reese JP; Schreiber S; Skoetz N; Störk S; Vehreschild JJ; Witzenrath M; Grill E;
Infection; 2023 Dec; 51(6):1679-1694. PubMed ID: 37231313
[TBL] [Abstract][Full Text] [Related]
8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
9. Depression and fatigue six months post-COVID-19 disease are associated with overlapping symptom constellations: A prospective, multi-center, population-based cohort study.
Weiß M; Gutzeit J; Appel KS; Bahmer T; Beutel M; Deckert J; Fricke J; Hanß S; Hettich-Damm N; Heuschmann PU; Horn A; Jauch-Chara K; Kohls M; Krist L; Lorenz-Depiereux B; Otte C; Pape D; Reese JP; Schreiber S; Störk S; Vehreschild JJ; Hein G;
J Affect Disord; 2024 May; 352():296-305. PubMed ID: 38360365
[TBL] [Abstract][Full Text] [Related]
10. Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation.
Kuchler T; Günthner R; Ribeiro A; Hausinger R; Streese L; Wöhnl A; Kesseler V; Negele J; Assali T; Carbajo-Lozoya J; Lech M; Schneider H; Adorjan K; Stubbe HC; Hanssen H; Kotilar K; Haller B; Heemann U; Schmaderer C
Angiogenesis; 2023 Nov; 26(4):547-563. PubMed ID: 37507580
[TBL] [Abstract][Full Text] [Related]
11. Variations and Predictors of Post-COVID Syndrome Severity in Patients Attending a Post-COVID Outpatient Clinic.
Lemhöfer C; Bahmer T; Baumbach P; Besteher B; Boekel A; Finke K; Katzer K; Lehmann-Pohl K; Lewejohann JC; Loudovici-Krug D; Nowka M; Puta C; Quickert S; Reuken PA; Walter M; Stallmach A
J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373706
[TBL] [Abstract][Full Text] [Related]
12. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study.
Augustin M; Schommers P; Stecher M; Dewald F; Gieselmann L; Gruell H; Horn C; Vanshylla K; Cristanziano VD; Osebold L; Roventa M; Riaz T; Tschernoster N; Altmueller J; Rose L; Salomon S; Priesner V; Luers JC; Albus C; Rosenkranz S; Gathof B; Fätkenheuer G; Hallek M; Klein F; Suárez I; Lehmann C
Lancet Reg Health Eur; 2021 Jul; 6():100122. PubMed ID: 34027514
[TBL] [Abstract][Full Text] [Related]
13. Seven Months after Mild COVID-19: A Single-Centre Controlled Follow-Up Study in the District of Constance (FSC19-KN).
Haberland E; Haberland J; Richter S; Schmid M; Hromek J; Zimmermann H; Geng S; Winterer H; Schneider S; Kollum M
Int J Clin Pract; 2022; 2022():8373697. PubMed ID: 36035510
[TBL] [Abstract][Full Text] [Related]
14. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics.
Schons M; Pilgram L; Reese JP; Stecher M; Anton G; Appel KS; Bahmer T; Bartschke A; Bellinghausen C; Bernemann I; Brechtel M; Brinkmann F; Brünn C; Dhillon C; Fiessler C; Geisler R; Hamelmann E; Hansch S; Hanses F; Hanß S; Herold S; Heyder R; Hofmann AL; Hopff SM; Horn A; Jakob C; Jiru-Hillmann S; Keil T; Khodamoradi Y; Kohls M; Kraus M; Krefting D; Kunze S; Kurth F; Lieb W; Lippert LJ; Lorbeer R; Lorenz-Depiereux B; Maetzler C; Miljukov O; Nauck M; Pape D; Püntmann V; Reinke L; Römmele C; Rudolph S; Sass J; Schäfer C; Schaller J; Schattschneider M; Scheer C; Scherer M; Schmidt S; Schmidt J; Seibel K; Stahl D; Steinbeis F; Störk S; Tauchert M; Tebbe JJ; Thibeault C; Toepfner N; Ungethüm K; Vadasz I; Valentin H; Wiedmann S; Zoller T; Nagel E; Krawczak M; von Kalle C; Illig T; Schreiber S; Witzenrath M; Heuschmann P; Vehreschild JJ;
Eur J Epidemiol; 2022 Aug; 37(8):849-870. PubMed ID: 35904671
[TBL] [Abstract][Full Text] [Related]
15. Post-COVID-19 syndrome symptoms after mild and moderate SARS-CoV-2 infection.
Al-Husinat L; Nusir M; Al-Gharaibeh H; Alomari AA; Smadi MM; Battaglini D; Pelosi P
Front Med (Lausanne); 2022; 9():1017257. PubMed ID: 36262270
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
18. Long-term health consequences of COVID-19 in survivors hospitalised at a tertiary care hospital and their correlation with acute COVID-19 severity and associated risk factors.
Jain V; Nabi N; Aggarwal S; Alam Z; Chandra K; Singh D; Kashyap V; Islam F; Kohli S
J Clin Nurs; 2024 Jan; 33(1):115-125. PubMed ID: 36802108
[TBL] [Abstract][Full Text] [Related]
19. Post-COVID-19 Syndrome: Incidence, Risk Factor, and the Most Common Persisting Symptoms.
Alghamdi SA; Alfares MA; Alsulami RA; Alghamdi AF; Almalawi AM; Alghamdi MS; Hazazi HA
Cureus; 2022 Nov; 14(11):e32058. PubMed ID: 36600841
[TBL] [Abstract][Full Text] [Related]
20. Post-acute sequelae of covid-19 six to 12 months after infection: population based study.
Peter RS; Nieters A; Kräusslich HG; Brockmann SO; Göpel S; Kindle G; Merle U; Steinacker JM; Rothenbacher D; Kern WV;
BMJ; 2022 Oct; 379():e071050. PubMed ID: 36229057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
